NovaScan’s leadership believes that improving the detection of cancer – be it in initial detection of cancer, during a procedure, or in post-procedural pathology – can improve patient outcomes, increase physician economics, and reduce the cost of care. We are committed to commercializing our platform technology for cancer detection, which we believe offers significant advantages over alternatives in soft tissue cancer detection. NovaScan’s first product, ColeRel, offers Mohs surgeons the opportunity for dramatically faster surgical procedures.